Looking ahead to the period from 2025 to 2035, several key trends and forecasted developments are expected to shape the rail ...
Caliway Biopharmaceuticals (TWSE-6919) announced today that CBL-514's second Phase 2b clinical study (CBL-0205), sprung across 15 sites in the U.S. and Canada, successfully met its primary and all ...